Physician profile
Holly Vanderwerff
NPI 1194195966
$4,915.79
in general payments reported to CMS, 2019-2025
29 companies · $1,707 in 2025
The $1,707 reported for 2025 was more than what 91% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $446 · 2023: $849 · 2024: $1,913 · 2025: $1,707.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,210 · Education: $260.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,209.50 |
| Education | $260.15 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $821.58 | 2023-2025 | Tremfya |
| Amgen INC. | $537.33 | 2023-2025 | Otezla, Otezla |
| Abbvie INC. | $423.77 | 2022-2025 | |
| Genzyme Corporation | $382.12 | 2023-2025 | |
| Sun Pharmaceutical Industries INC. | $381.43 | 2023-2025 | Ilumya |
| Incyte Corporation | $271.75 | 2023-2025 | Opzelura |
| Regeneron Healthcare Solutions, INC. | $267.29 | 2023-2025 | Dupixent |
| Lilly USA, LLC | $250.58 | 2022-2025 | Taltz, Olumiant, Ebglyss |
| Novartis Pharmaceuticals Corporation | $202.61 | 2023-2025 | |
| Ucb, INC. | $197.82 | 2024-2025 | Bimzelx |
| Organon LLC | $137.45 | 2024-2025 | Hadlima, Vtama |
| Arcutis Biotherapeutics, INC. | $134.52 | 2023-2025 | Zoryve |
| Inspire Medical Systems, INC. | $133.49 | 2022 | |
| E.R. Squibb & Sons, L.L.C. | $113.81 | 2024-2025 | Sotyktu |
| Dermavant Sciences, INC. | $102.13 | 2023-2024 | Vtama |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $98.46 | 2022 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $69.00 | 2023-2024 | Arazlo, Jublia, Cabtreo |
| Boehringer Ingelheim Pharmaceuticals, INC. | $67.33 | 2023-2024 | Spevigo |
| Pfizer INC. | $67.24 | 2025 | |
| Biofrontera INC. | $50.25 | 2023 | Ameluz, Xepi, Bf-Rhodoled |
| Leo Pharma INC. | $37.22 | 2025 | Anzupgo |
| Kyowa Kirin, INC. | $36.46 | 2024-2025 | Poteligeo |
| Alnylam Pharmaceuticals INC. | $28.34 | 2024 | Givlaari |
| Alexion Pharmaceuticals, INC. | $20.98 | 2025 | Koselugo |
| Botanix Sb INC | $19.63 | 2025 | Sofdra |
| Krystal Biotech INC | $18.90 | 2025 | Vyjuvek |
| Almirall LLC | $17.04 | 2023 | Seysara |
| Strata Skin Sciences, INC. | $14.09 | 2025 | Xtrac |
| Janssen Pharmaceuticals, INC | $13.17 | 2025 | Tremfya |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Holly Vanderwerff listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.